EC
ELDN icon

EcoR1 Capital’s Eledon Pharmaceuticals ELDN Stock Holding History

EcoR1 Capital’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,115,721
Closed -$11.9M – 73
2021
Q1 		$11.9M Buy
+1,115,721
New +$16.8M 0.53% 27

Other funds holding ELDN

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital's ELDN Position: Q2 2021 in Review

EcoR1 Capital sold out of Eledon Pharmaceuticals (ELDN) in Q2 2021, closing a stake of 1,115,721 shares — an estimated $11.9M sold.

EcoR1 Capital first reported a position in ELDN in Q1 2021 and held it in 1 quarter. The position peaked at $11.9M in Q1 2021. 34 funds tracked by Wall St. Rank hold ELDN as of Q2 2021.

  • EcoR1 Capital reported no remaining Eledon Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • EcoR1 Capital sold 1,115,721 Eledon Pharmaceuticals shares in Q2 2021, an estimated $11.9M.
  • EcoR1 Capital first reported a position in Eledon Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • EcoR1 Capital's Eledon Pharmaceuticals position peaked at $11.9M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2021.

Based on EcoR1 Capital's 13F filing for Q2 2021, filed 16 Aug 2021.